The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout

被引:15
作者
Huang, Yuan-Yuan [1 ,2 ]
Ye, Zhuang [1 ]
Gu, San-Wei [1 ]
Jiang, Zhen-Yu [1 ]
Zhao, Ling [1 ,3 ]
机构
[1] First Hosp Jilin Univ, Dept Rheumatol, 71 Xinmin St, Changchun 130024, Jilin, Peoples R China
[2] First Hosp Jilin Univ, Outpatient Dept Paediat, Changchun, Jilin, Peoples R China
[3] Jilin Univ Pharmaceut Sci, Lab Biomed, Changchun, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
Febuxostat; serum urate; hyperuricaemia; gout; URIC-ACID; HYPERURICEMIA; RISK; INHIBITOR; DISEASE; SAFETY;
D O I
10.1177/0300060520902950
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective To measure the effect of febuxostat on the serum levels of uric acid (sUA) and the proinflammatory cytokines interleukin (IL)-6, IL-17 and tumour necrosis factor-alpha (TNF-alpha) in Chinese Han patients with gout and hyperuricaemia. Methods This randomized, double-blind, placebo-controlled pilot study enrolled patients with gout and hyperuricaemia (sUA >= 8 mg/dl). Patients were randomized to receive either febuxostat 80 mg or placebo once daily for 24 weeks. The serum levels of sUA, IL-6, IL-17 and TNF-alpha were measured at weeks 0 (baseline), 2, 4, 8, 12, 16 and 24. Baseline clinical and demographic characteristics were recorded for all patients. Results A total of 156 patients were randomized: placebo group (n = 78) and febuxostat group (n = 78). The febuxostat group showed a significantly greater reduction in sUA compared with the placebo group. Serum uric acid concentration was reduced below 8 mg/dl in 46 of 61 patients (75.4%) by week 24. There were also reductions in the serum levels IL-6, IL-17 and TNF-alpha in the febuxostat group. In the febuxostat group, 10 of 78 patients (12.82%) discontinued treatment due to adverse drug reactions. Conclusion Febuxostat reduced the levels of sUA, TNF-alpha, IL-6 and IL-17, but there were some side-effects.
引用
收藏
页数:9
相关论文
共 23 条
  • [11] High serum uric acid is associated with increased cardio-ankle vascular index (CAVI) in healthy Japanese subjects: A cross-sectional study
    Nagayama, Daiji
    Yamaguchi, Takashi
    Saiki, Atsuhito
    Imamura, Haruki
    Sato, Yuta
    Ban, Noriko
    Kawana, Hidetoshi
    Nagumo, Ayako
    Shirai, Kohji
    Tatsuno, Ichiro
    [J]. ATHEROSCLEROSIS, 2015, 239 (01) : 163 - 168
  • [12] GOSPEL 2-Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age
    Pascart, Tristan
    Lancrenon, Sylvie
    Lanz, Sabine
    Delva, Catherine
    Guggenbuhl, Pascal
    Lambert, Charles
    Aubert, Jean-Pierre
    Saraux, Alain
    Ea, Hang-Korng
    Liote, Frederic
    [J]. JOINT BONE SPINE, 2016, 83 (06) : 687 - 693
  • [13] Gout as autoinflammatory disease: New mechanisms for more appropriated treatment targets
    Punzi, Leonardo
    Scanu, Anna
    Ramonda, Roberta
    Oliviero, Francesca
    [J]. AUTOIMMUNITY REVIEWS, 2012, 12 (01) : 66 - 71
  • [14] IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation
    Raucci, Federica
    Iqbal, Asif J.
    Saviano, Anella
    Minosi, Paola
    Piccolo, Marialuisa
    Irace, Carlo
    Caso, Francesco
    Scarpa, Raffaele
    Pieretti, Stefano
    Mascolo, Nicola
    Maione, Francesco
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 147
  • [15] Reinders MK, 2010, CLIN INTERV AGING, V5, P7
  • [16] Febuxostat for the treatment of hyperuricaemia in gout
    Robinson, Philip C.
    Dalbeth, Nicola
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (11) : 1289 - 1299
  • [17] In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters
    Shen, Zancong
    Yeh, Li-Tain
    Wallach, Kathleen
    Zhu, Nanqun
    Kerr, Brad
    Gillen, Michael
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 443 - 452
  • [18] Gout and risk of knee replacement for severe knee osteoarthritis in the Singapore Chinese Health Study
    Teng, G. G.
    Leung, Y. Y.
    Ang, L. -W.
    Yuan, J. -M.
    Koh, W. -P.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2017, 25 (12) : 1962 - 1968
  • [19] Efficacy and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Kidney Transplant Recipients
    Tojimbara, T.
    Nakajima, I.
    Yashima, J.
    Fuchinoue, S.
    Teraoka, S.
    [J]. TRANSPLANTATION PROCEEDINGS, 2014, 46 (02) : 511 - 513
  • [20] Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy
    Tsutsumi, Z
    Moriwaki, Y
    Takahashi, S
    Ka, T
    Yamamoto, T
    [J]. CLINICA CHIMICA ACTA, 2004, 339 (1-2) : 117 - 122